DALLAS, January 30, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Candidiasis - Pipeline Review, H1 2015" to its store. This report provides an overview of the Candidiasis's therapeutic development pipeline with cutting-edge Candidiasis updates and news.
The report "Candidiasis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.
Candidiasis is a fungal infection that can affect areas such as skin, genitals, throat, mouth and blood. There are over twenty types of Candida yeasts that can cause infection in humans. When Candidiasis affects the mouth it is commonly called thrush and when Candidiasis affects the vagina it is commonly referred to as a yeast infection. Candidiasis of skin can occur anywhere on the skin, but it is most likely to occur on areas where the skin is folded.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies discussed in this Candidiasis - Pipeline Review, H1 2015 report include Actavis plc, Aureogen Biosciences, Inc., Basilea Pharmaceutica AG, Biomar Microbial Technologies, Cellceutix Corporation, Eisai Co., Ltd., General Biologicals Corporation, Grupo Ferrer Internacional, S.A., iCo Therapeutics Inc., Novabiotics Ltd, NovaDigm Therapeutics, Inc., Novartis AG, Onxeo SA, Panacela Labs, Inc., Scynexis, Inc., Sealife PHARMA GMBH, Sequella, Inc., Viamet Pharmaceuticals, Inc., Wellstat Vaccines, LLC. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269521 . (This is a premium report priced at US$2000 for a single user License.)
Featured News and Press Releases:
- Nov 03, 2014: Basilea Reports Granting Of U.S. Orphan Drug Designation To Isavuconazole For The Treatment Of Invasive Candidiasis
- Oct 16, 2014: Basilea Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study
- Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014
- Jul 16, 2014: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
- Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis
- Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig
- Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161
- Nov 18, 2013: Cellceutix Identifies PMX-1408 as treatment Gram-Negative and Candida Fungal Infections
- Nov 18, 2013: Cellceutix Identifies Drug Candidate for Candida Fungal Infections
- Sep 26, 2013: NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal
Scope of Candidiasis Pipeline Review, H1 2015 covers: A snapshot of the global therapeutic landscape of Candidiasis; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products.
Global Markets Direct report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Explore more reports on Infectious Diseases Therapeutics here : http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
Related reports on Infectious Diseases Therapeutics
The report "Community Acquired Pneumonia - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Community Acquired Pneumonia. Community-acquired pneumonia (CAP) is pneumonia acquired infectiously from normal social contact as opposed to being acquired during hospitalization. In community-acquired pneumonia, individuals who have not recently been hospitalized develop an infection of the lungs (pneumonia).
The report "Typhoid Fever - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Typhoid Fever. Typhoid fever s a common worldwide bacterial disease transmitted by the ingestion of food or water contaminated with the feces of an infected person, which contain the bacterium Typhi. The disease has received various names, such as gastric fever, enteric fever, abdominal typhus, infantile remittent fever, slow fever, nervous fever and pythogenic fever. The bacterium that causes typhoid fever may be spread through poor hygiene habits and public sanitation conditions, and sometimes also by flying insects feeding on feces.
RnRMarketResearch.com is a database of selected syndicated market reports for global and regional industries including but not limited to life sciences, information technology and telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research